These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11503532)

  • 41. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
    Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
    Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individualising hormone replacement therapy.
    Attilakos G; Wardle PG
    Practitioner; 2002 May; 246(1634):295-8, 302, 305 passim. PubMed ID: 12043347
    [No Abstract]   [Full Text] [Related]  

  • 43. Does estrogen/progestin therapy in post-menopausal women decrease their risk of fracture?
    Groh KW; Stevermer JJ
    J Fam Pract; 2001 Nov; 50(11):926. PubMed ID: 11711004
    [No Abstract]   [Full Text] [Related]  

  • 44. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response.
    Hartsfield CL; Connelly MT; Newton KM; Andrade SE; Wei F; Buist DS
    J Natl Cancer Inst Monogr; 2005; (35):113-5. PubMed ID: 16287896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hormone substitution by injectable preparations and skin implants].
    Kuhl H
    Gynakologe; 1986 Dec; 19(4):241-7. PubMed ID: 3817596
    [No Abstract]   [Full Text] [Related]  

  • 46. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A clinician's review of the WHI-related literature.
    Speroff L
    Int J Fertil Womens Med; 2004; 49(6):252-67. PubMed ID: 15751264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular effects of estrogen replacement therapy.
    Chae CU; Manson JE
    Adv Intern Med; 2001; 47():47-88. PubMed ID: 11795080
    [No Abstract]   [Full Text] [Related]  

  • 49. [Climacteric--from the viewpoint of the established gynecologist. Interview by Jeanette Gerhardt].
    Gericke DS
    Geburtshilfe Frauenheilkd; 1994 Jan; 54(1):IX-X. PubMed ID: 8150240
    [No Abstract]   [Full Text] [Related]  

  • 50. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension.
    Javeshghani D; Sairam MR; Neves MF; Schiffrin EL; Touyz RM
    J Hypertens; 2006 Jul; 24(7):1365-73. PubMed ID: 16794486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Sexual dysfunction in the menopause. Incidence, pharmacological treatment and side effects].
    Gregersen N; Hilmand CB; Jensen PT; Giraldi AG
    Ugeskr Laeger; 2006 Feb; 168(6):559-63. PubMed ID: 16476214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormone replacement therapy aggravates postmenopausal urinary incontinence.
    Prescrire Int; 2006 Aug; 15(84):137-8. PubMed ID: 16989027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The trials and tribulations of long-term postmenopausal hormone therapy.
    MacLennan AH
    Obstet Gynecol Surv; 2004 Feb; 59(2):65-7. PubMed ID: 14752298
    [No Abstract]   [Full Text] [Related]  

  • 54. The lost promise of hormone replacement therapy and heart disease.
    Maas AH
    Semin Vasc Med; 2004 May; 4(2):135-44. PubMed ID: 15478034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Postmenopausal hormone therapy: the way ahead.
    Pines A
    Maturitas; 2007 May; 57(1):3-5. PubMed ID: 17376615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):5-7. PubMed ID: 12553323
    [No Abstract]   [Full Text] [Related]  

  • 57. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Good science or good marketing?
    Head K
    Altern Med Rev; 2002 Aug; 7(4):274-5. PubMed ID: 12197780
    [No Abstract]   [Full Text] [Related]  

  • 59. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weighing the risks and benefits of hormone therapy.
    Toth S; Blanchard E; Herman L; Larson L; Léger MM; McNellis R; Quigley T; Van Dyke E
    JAAPA; 2003 Jun; 16(6):45-7. PubMed ID: 14968505
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.